Skip to main content
Clinical Trials/NCT04066283
NCT04066283
Recruiting
Not Applicable

Novel Evaluations of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Women Compared to Age Group-Matched Cisgender Adults

University of Colorado, Denver1 site in 1 country30 target enrollmentApril 17, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Transgender
Sponsor
University of Colorado, Denver
Enrollment
30
Locations
1
Primary Endpoint
Evaluation of endothelial function (flow-mediated dilation (FMD)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in younger versus older transgender women (people who were assigned male at birth but whose gender identity is female). Data will also be compared to those from cisgender women and men.

Registry
clinicaltrials.gov
Start Date
April 17, 2019
End Date
November 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 18-40 years old or 50-75 years old
  • Identify as a transgender woman
  • Have taken estradiol and spironolactone for at least one year
  • Currently taking oral or transdermal estradiol

Exclusion Criteria

  • Don't identify as a transgender woman
  • Not currently taking estradiol or spironolactone
  • Have been on estradiol and spironolactone for less than one year
  • History of orchiectomy
  • Current tobacco smoker
  • Current illicit drug use
  • History of prior or active estrogen-dependent neoplasms
  • Acute liver or gallbladder disease
  • Venous thromboembolism
  • Hypertriglyceridemia \>500 mg/dL

Outcomes

Primary Outcomes

Evaluation of endothelial function (flow-mediated dilation (FMD)

Time Frame: Baseline

Brachial artery flow-mediated dilation (FMD), as measured by ultrasound.

Secondary Outcomes

  • Plasma lipid concentrations: total cholesterol(Baseline)
  • Insulin sensitivity(Baseline)
  • Whole body composition: Percent Lean Mass(Baseline)
  • Evaluation of carotid artery compliance(Baseline)
  • Evaluation of oxidant burden: oxidized LDL(Baseline)
  • Evaluation of vascular endothelial cell inflammation: NFkB(Baseline)
  • Evaluation of carotid artery beta stiffness index(Baseline)
  • Weight changes(Baseline)
  • Depression symptoms(Baseline)
  • Carotid artery intimal-medial thickness(Baseline)
  • Evaluation of vascular endothelial cell inflammation: IL-6(Baseline)
  • Evaluation of vascular endothelial cell inflammation: CRP(Baseline)
  • Blood pressure(Baseline)
  • Evaluation of oxidant burden: nitrotyrosine(Baseline)
  • Evaluation of vascular endothelial cell inflammation: MCP-1(Baseline)
  • Plasma lipid concentrations: triglycerides(Baseline)
  • Whole body composition: Percent Fat Mass(Baseline)
  • Regional body composition: Percent Lean Mass(Baseline)
  • D-Dimer(Baseline)
  • Energy intake(3 days)
  • Regional body composition: Percent Fat Mass(Baseline)
  • Appetite ratings(Baseline)
  • Appetite-related peptides(Baseline)
  • Alcohol use(Baseline)
  • Physical activity monitoring(7 days)

Study Sites (1)

Loading locations...

Similar Trials